Eficacia y seguridad de asociar ezetimiba a dosis bajas de atorvastatina en la hipercolesterolemia asociada al tratamiento antirretroviral en pacientes con el virus de la inmunodeficiencia humana

Prospective, open-label study of HIV-patients with HAART-related dyslipidaemia to analyse the efficacy and safety of ezetimibe plus low-dose atorvastatin in HIV-patients on HAART who do not reach LDL-C goals with atorvastatin. Changes in plasma levels of lipids, cardiovascular risk (CVR) at 10 years (Frahmingam equation), immunovirological parameters, CK and ALT levels were analysed. Twenty seven patients were included, thirteen (48%) achieved LDL-C goals, and a reduction was observed in total cholesterol, LDL-C, and the percentage of patients with a 10 year CVR > 10%. Mean CD4 cells count increased, and all patients maintained undetectable HIV viral load. No adverse events were observed. Adding ezetimibe to low-dose atorvastatin is safe and effective for HAART-related hypercholesterolaemia.